| Literature DB >> 32783353 |
Linde C M van Dongen1,2,3, Ellen Wingbermühle1,2,3,4, Alexander J M Dingemans3, Anja G Bos-Roubos1,2, Karlijn Vermeulen3,5, Monica Pop-Purceleanu6, Tjitske Kleefstra2,3, Jos I M Egger1,2,3,4.
Abstract
Witteveen-Kolk syndrome (WITKOS) is a rare neurodevelopmental disorder characterized by developmental delay/intellectual disability, facial dysmorphisms, and short stature. The syndrome is caused by loss of function of switch-insensitive 3 transcription regulator family member A (SIN3A). Regarding behavioral functioning, Autism Spectrum Disorders (ASD), obsessive-compulsive behaviors, as well as Attention-Deficit/Hyperactivity Disorder symptoms (ADHD) have been suggested. The present study explores various aspects of neurocognitive functioning in five individuals (age range 10-23) with WITKOS. Medical records and results of extensive neuropsychological assessment are used to describe developmental trajectories and neurocognitive profiles. Systematic analysis of medical records displays developmental difficulties described as ASD or ADHD in childhood, sleep problems and internalizing problems during adolescence. Results of cognitive assessments indicate profoundly disabled (n = 1), mildly disabled (n = 2), borderline (n = 1), and average (n = 1) levels of intelligence. Furthermore, results indicate weaknesses in speed of information processing/sustained attention in all participants, and difficulties in planning and maintaining overview in three participants. Furthermore, parent reports of behavioral functioning primarily suggest problems in social functioning. Implications of both cognitive problems and social-emotional vulnerabilities for counseling are discussed and supplemented with suggestions for interventions.Entities:
Keywords: SIN3A; Witteveen-Kolk syndrome; case-series; cognition; contextual neuropsychology; neurodevelopmental disorder
Mesh:
Year: 2020 PMID: 32783353 PMCID: PMC7540409 DOI: 10.1002/ajmg.a.61775
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802
Cognitive and behavioral assesment
| Patient | Mean normative |
| |||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | (i.e., | ||
| Cognition | |||||||
| Intelligence | FSIQ | −2.3 | −1.7 | 21 | −2.5 | −0.6 | 4/5 |
| VIQ/VCI | −1.7 | NA | NA | −1.3 | −0.7 | 1/4 | |
| PIQ/PRI | −2.6 | NA | NA | −2.7 | −0.4 | 2/4 | |
| WMI | NA | NA | NA | −2.8 | −0.6 | 1/2 | |
| PSI | NA | NA | NA | –2.0 | −0.5e | 1/2 | |
| Attention | D2 (TN) | −1.6 | −1.5 | NA | −2.0 | −2.0 | 4/4 |
| D2 (F) | 1.1 | −1.5 | NA | 0.5 | 0.9 | 1/4 | |
| Executive functioning | Key search | −2.0 | −0.7 | NA | −2.0 | 0.7 | 2/4 |
| Zoo map | −2.0 | −0.7 | NA | −2.6 | −1.6 | 3/4 | |
| Zoo map 2 | −2.4 | 0.8 | NA | −2.3 | 0.7 | 2/4 | |
| CFT Rey copy | −2.0 | −1.5 | NA | −1.3 | −1.1 | 2/4 | |
| Memory | CFT Rey recall | −2.6 | −2.6 | NA | <−1.3 | −0.8 | 2/4 |
| RAVLT immediate recall | −0.6 | <−1.3 | NA | −1.3 | −1.1 | 0/4 | |
| RAVLT delayed recall | 1.1 | > 1.4 | NA | −0.4 | −1.1 | 0/4 | |
| Social cognition | ToM test R | −0.5 | <−2.0 | NA | −2.0 | 0.0 | 2/4 |
| ERT | NA | −2.0 | NA | −0.8 | −1.4 | 1/3 | |
| Visuoconstruction | Beery VMI | −0.2 | −0.7 | NA | NA | −0.7 | 0/3 |
| Beery visual perception | −0.7 | −1.2 | NA | NA | −1.2 | 0/3 | |
| Beery motor coordination | −0.5 | −0.7 | NA | NA | −0.7 | 0/3 | |
| Behavior | |||||||
| Attention problems | − | + | + | NA | + | 3/4 | |
| Anxious/depressed | + | − | + | − | − | 2/5 | |
| Social problems | − | + | + | + | + | 4/5 | |
| Behavior problems | − | − | ± | NA | − | 0/3 | |
| Thought problems | − | − | + | − | − | 1/4 | |
Note: +, present (≥1.5 SD); − absent (<1 SD); ± present but subtle (1–1.5 SD).
Abbreviations: Beery VMI, beery‐buktenica developmental test of visual‐motor integration; CFT Rey, Rey–Osterrieth complex figure test; D2 (TN), d2 sustained‐attention test (total number of characters processed); D2 (F), d2 sustained‐attention test (total number of errors); ERT, emotion recognition task; FSIQ, full scale intelligence quotient; Key Search, Zoo Map 1 and Zoo Map 2 are subtest of the behavioural assessment of the dysexecutive syndrome (for Children); NA: results not available; PIQ, performal intelligence quotient; PRI, perceptual reasoning index; PSI, processing speed index; RAVLT, rey auditory verbal learning test; ToM‐test R, theory of mind test‐revised; VIQ, verbal intelligence quotient; VCI, verbal comprehension index; WMI, working memory index.
Based on WISC‐III; IQ scores are 65, 74, and 61, respectively.
Based on SON‐R; IQ score is 74.
Based on BSID‐II, developmental age in months.
Based on WAIS‐IV; IQ scores are 63, 81, 60, 58, and 70, respectively.
Based on WISC‐V; IQ scores are 91, 89, 94–100, 91, and 92, respectively.
Based on the subtests Affect Recognition and Theory of Mind in the NEPSY‐II.
Based on the subscales: Attention problems (CBCL), Hyperactivity/inattention (SDQ).
Based on the subscales: Withdrawn/depressed (CBCL) + Anxious/depressed (CBCL), Emotional symptoms (SDQ), Affective disorder (PIMRA) + Anxiety disorder (PIMRA), Depressive disorder (Mini PASS‐ADD) + Anxiety disorder (PIMRA).
Based on the subscales: Social problems (CBCL), Peer relations (SDQ) or Autism spectrum disorder (social skills, Mini PASS‐ADD).
Based on the subscales: Rule‐breaking behavior (CBCL) + Aggressive behavior (CBCL) or Conduct problems (SDQ).
Based on the subscales: Thought problems (CBCL), Schizophrenia (PIMRA) or Psychotic disorder (Mini PASS‐ADD).
Patient characteristics
| Demographical | Patient | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| Gender | F | M | M | M | F | |
| Details | Age | 14 | 10 | 12 | 23 | 10 |
| Genetic details | Chromosome | Chr15(GRCh37):g.75702623_75702626del | Chr15(GRCh37):g.75682058_75682059del | Chr15(GRCh37):g.75704038dup | Chr15(GRCh37):g.75693133G>A | Chr15(GRCh37):75694230_75694231del |
| Mutation | NM_001145357.1:c.1010_1013del | NM_001145358.1:c.2955_2956del | NM_001145358.1:c.803dup | NM_001145358.1:c.1675C>T | NM_001145357.1:c.1488_1498del | |
| Protein | p.Lys337fs | p.Glu985fs | p.Leu269fs | p.Arg559* | p.Arg497fs | |
| Genetic tests | EYA1, DGUOK, POLG, array, karyotype, MELAS, WES (ID panel + open exome) | Karyotype, fragile X, array, WES (ID panel + open exome) | BRAF, MAP2K1, MAP2K2, array, WES (ID panel + open exome) | Array, karyotype, WES (ID panel) | Karyotype, array, WES (craniofacial anomalies + ID panel) | |
| Additional genetic findings | Polymorfism in MELAS | – | FLNA: c.7172G>A (p.[Arg2391His]) | – | Gain 5q21.2 (paternally), deletion 10q21.2 (maternally) | |
| Medical characteristics | Pregnancy abnormalities | – | – | – | – | Born at 32 weeks |
| Vision | Hypermetropia was successfully corrected with glasses | – | Hypermetropia was successfully corrected with glasses | – | – | |
| Hearing | Hearing aids | Ear tubes as of regular ears infections | Hearing aids | – | Ear tubes as of regular ears infections | |
| Epilepsy | Tonic clonic seizures until the age of 2 | Two incidental seizures during puberty | Started at the age of 2 with a incidence of twice a week, treated with depakine and Frisium | – | – | |
| Brain MRI | Enlarged intra and extra‐cerebral spaces | Enlarged lateral ventricles, agenesis of the corpus callosum | Bilateral hypomyelination of the insular region, enlarged gyri, lower position of the cerebellar tonsils | NA | NA | |
| Other | – | – | Central sleep apnea, treated with Acetazolam and supplemental oxygen | – | – |
Abbreviations: F, female; M, male; NA, not available.